Fox Chase Cancer Center and Temple Health Physicians and Scientists Present Research at the American Society of Hematology 2024 Annual Meeting

Link to
Fox Chase Cancer Center and Temple Health physicians and scientists will participate in the presentation and discussion of eight research projects at the American Society of Hematology (ASH) 2024 Annual Meeting.

PHILADELPHIA (December 6, 2024) — Fox Chase Cancer Center and Temple Health physicians and scientists will participate in the presentation and discussion of eight research projects at the American Society of Hematology (ASH) 2024 Annual Meeting, which is being held December 7-10 in San Diego.

Saturday, December 7

2091: “Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study,” Peter Abdelmessieh, MD, Fox Chase Cancer Center; Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products Poster; Session 711; 5:30 PM-7:30 PM; Location: Halls G-H.

2214: “Clinical Validation of a Personalized NHL-TME Model System: One-on-One Comparison between Modeled Drug Responses and Patients’ Clinical Responses,” Marcus Messmer, MD, Fox Chase Cancer Center, Y. Lynn Wang, MD, PhD, FCAP, Fox Chase Cancer Center; Emerging Tools, Techniques and Artificial Intelligence in Hematology Poster; Session 803; 5:30 PM-7:30 PM; Location: Halls G-H. 

1573: “Epigenetic Adaptation Promotes Cellular Resilience in Senescence-Like AML Cells,” Cihangir Duy, PhD, Fox Chase Cancer Center; Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment Poster; Session 619; 5:30 PM-7:30 PM; Location: Halls G-H.

2165: “Effects of Post-Transplant Cyclophosphamide on Outcomes of Allogenic Stem Cell Transplant Are Different Between Older and Younger Adult Patients: A Single Institutional Experience,” Daniel Stapor, MD, Temple University Health System, Fox Chase Cancer Center, Asya Varshavsky Yanovsky, MD, PhD, Fox Chase Cancer Center; Allogenic Transplantation: Long-term Follow-up, Complications and Disease Recurrence Poster; Session 723; 5:30 PM-7:30 PM; Location: Halls G-H.

1602: “Inosine Monophosphate Dehydrogenase-2 (IMPDH2) as the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications,” Johnvesly Basappa, PhD, Fox Chase Cancer Center; Lymphomas: Translational, Molecular and Genetic Poster; Session 621; 5:30 PM-7:30 PM; Location: Halls G-H.

Sunday, December 8

3739: “Disparities in Psychological Distress and Coping Behaviors Amongst Patients with Indolent Hematologic Malignancies,” Tammarah Sklarz, MD, Fox Chase Cancer Center; Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders Poster; Session 906; 6:00 PM-8:00 PM; Location: Halls G-H.  

Monday, December 9

4120: “Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications,” Johnvesly Basappa, PhD, Fox Chase Cancer Center; Lymphoid Oncogenesis Poster; Session 603; 6:00 PM-8:00 PM; Location: Halls G-H.

5117: “Sex, Race, and Geographic Disparities in Early Age at Onset Hematologic Malignancies,” Tammarah Sklarz, MD, Fox Chase Cancer Center; Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders Poster; Session 906; 6:00 PM-8:00 PM; Location: Halls G-H. 

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text